A cross-comparison study using survival data and safety profiles from two clinical trials was conducted to assess the impact of LAG-3/PD-1 inhibition (relatlimab–nivolumab therapy) versus CTLA-4/PD-1 inhibition (ipilimumab–nivolumab) in untreated advanced melanoma patients (130). Here, CTLA4 is linked to melanoma.